This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Calliditas Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Calliditas Therapeutics şirketinin toplam hissedar öz sermayesi SEK106.8M ve toplam borcu SEK982.5M olup, bu da borç-öz sermaye oranını 920% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK1.7B ve SEK1.6B dir.

Anahtar bilgiler

920.0%

Borç/özkaynak oranı

SEK 982.49m

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 797.28m
Eşitlik	SEK 106.79m
Toplam yükümlülükler	SEK 1.64b
Toplam varlıklar	SEK 1.75b

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: LC8A 'nin kısa vadeli varlıkları ( SEK1.2B ) kısa vadeli yükümlülüklerini ( SEK429.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: LC8A 'un kısa vadeli varlıkları ( SEK1.2B ) uzun vadeli yükümlülüklerini ( SEK1.2B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: LC8A 'nin net borç/öz sermaye oranı ( 173.4% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: LC8A şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 920% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: LC8A şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: LC8A tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

This company listing is no longer active

Calliditas Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nasdaq Stockholm Decides to Delist Calliditas Therapeutics

Calliditas Resolves to Apply for Delisting of the Common Shares from Nasdaq Stockholm, ADS from Nasdaq Global Select Market

Asahi Kasei Intends to Promote Delisting of the Shares in Calliditas Therapeutics from Nasdaq Stockholm

Recent updates

Calliditas Therapeutics AB (publ) Announces Board Changes

Nasdaq Stockholm Decides to Delist Calliditas Therapeutics

Calliditas Therapeutics AB (publ)(OM:CALTX) dropped from OMX Nordic All-Share Index

Calliditas Resolves to Apply for Delisting of the Common Shares from Nasdaq Stockholm, ADS from Nasdaq Global Select Market

Asahi Kasei Intends to Promote Delisting of the Shares in Calliditas Therapeutics from Nasdaq Stockholm

Calliditas Therapeutics AB Announces the European Commission Grant Full Marketing Authorization for Kinpeygo

Calliditas Therapeutics AB Announces Positive Transform Phase 2b Topline Data in Primary Biliary Cholangitis

Calliditas Therapeutics AB (publ) Provides Setanaxib Patent Update

Calliditas Partner Stada Receives Positive Chmp Opinion Recommending Full Approval for Kinpeygo[®] for the Treatment of Iga Nephropathy

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and other shareholders for SEK 11.2 billion.

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and others shareholders for SEK 11.2 billion.

Calliditas Therapeutics AB (Publ) Reaffirms Earnings Guidance for the Year Ending December 31, 2024

Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib

Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results

Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

Calliditas Therapeutics AB Announces an Additional Seven Year Orphan Drug Exclusivity Period for TARPEYO

Calliditas Therapeutics AB Provides Patent Update

Calliditas Therapeutics AB Provides Preliminary Revenue Guidance for the Full Year 2023

Calliditas Therapeutics AB Announces Full FDA Approval of TARPEYO

Calliditas Therapeutics AB (publ) Receives Notice of Allowance for United States Patent Application Covering TARPEYO

Calliditas Therapeutics AB Announces the Initiation of A Phase 2 Clinical Study to Evaluate Setanaxib in Alport Syndrome

Calliditas Therapeutics AB Presents Additional Data Analyses from NefIgArd Phase 3 Trial at American Society of Nephrology Kidney Week 2023

Calliditas Therapeutics' Nomination Committee Composition for the Agm 2024

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023

Calliditas Therapeutics AB Presents Data from the Nefigard Phase 3 Trial At the 17Th International Symposium on Iga Nephropathy (Iigann) Tokyo 2023

STADA and Calliditas Therapeutics AB Announce Submission of Request to EMA for CHMP to Convert Conditional Marketing Authorization for Kinpeygo to Standard, or Full, Marketing Authorization

Calliditas Therapeutics AB (publ) to Report Q1, 2024 Results on May 16, 2024

Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon®? for the Treatment of IgA Nephropathy

Calliditas Therapeutics AB (publ) announces that FDA Grants Priority Review for Full Approval of Tarpeyo for the Treatment of IgA Nephropathy

Calliditas Therapeutics AB (Publ) Provides Sales Guidance for Year Ending December 31, 2023

Calliditas Therapeutics AB (publ) Announces Supportive Interim Data from Phase 2 Head and Neck Cancer Trial with Lead Nox Inhibitor Candidate, Setanaxib

Calliditas Therapeutics AB Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO

Calliditas Therapeutics AB (publ) Announces Board Changes

Calliditas Therapeutics AB (Publ) Provides Earnings Outlook for the Year Ending December 31, 2023

Calliditas Therapeutics AB (publ) Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA Nephropathy

Calliditas Therapeutics AB (publ) to Report Nine Months, 2023 Results on Nov 16, 2023

Calliditas Therapeutics Announces China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

Calliditas' Partner Everest Medicine's New Drug Application for Nefecon Is Accepted by the China Nmpa

Calliditas Therapeutics AB (Publ) Announces Nomination Committee Composition for the Agm 2023

Calliditas Therapeutics AB (publ) Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO[®] (budesonide) in IgA Nephropathy

Calliditas Therapeutics AB (publ) to Report Q1, 2023 Results on May 17, 2023

Calliditas Therapeutics AB (publ) Announces European Commission Approves Kinpeygo® for Adults with Primary IgA Nephropathy

Calliditas Therapeutics AB Announces Executive Appointments

Calliditas Therapeutics AB (Publ) Announces Board Changes

Calliditas Therapeutics AB (Publ) Announces First Patient Randomized in Phase 2 Trial in Head and Neck Cancer

Calliditas Therapeutics AB Launches an Online Patient Platform

Calliditas Therapeutics AB (publ) Updates First Patient Randomized in Pivotal TRANSFORM Study with Setanaxib

FdA Grants Calliditas Therapeutics Accelerated Approval of Tarpeyo™ (Budesonide) to Reduce Proteinuria in Iga Nephropathy

U.S. Food and Drug Administration Extends Calliditas Therapeutics AB (Publ)'s the PDUFA Goal Date for New Drug Application

Calliditas Therapeutics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 324 million.

Calliditas Therapeutics AB Receives FDA Fast Track Designation for setanaxib in PBC

Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency

U.S. Food and Drug Administration Grants Priority Review for Nefecon of Calliditas Therapeutics AB, for Patients with IgA Nephropathy

Calliditas Therapeutics AB (publ) Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy

Calliditas Therapeutics AB (Publ) Announces Executive Appointments

Calliditas Therapeutics AB (publ) to Report Fiscal Year 2020 Final Results on Apr 27, 2021

Calliditas Therapeutics AB (Publ) Announces That the First Patient Has Been Dosed in the Global Open-Label Extension of the Phase 3 Nefigard Study

Calliditas Therapeutics AB Announces Full Enrollment of the Phase 3 NefIgArd Trial

Calliditas Therapeutics AB (publ) Announces Clinical Development Plan for Setanaxib

Calliditas Therapeutics AB (publ), Annual General Meeting, May 27, 2021

Calliditas Therapeutics AB (publ) to Report First Half, 2021 Results on Aug 19, 2021

Calliditas Therapeutics AB (publ) Reports Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Calliditas Therapeutics AB (publ) Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Calliditas Therapeutics AB (publ) Announces the Last Visit of the 200Th Patient Has Taken Place in Part A of the Pivotal NeflgArd Phase 3 Study

Calliditas Therapeutics AB (publ) (OM:CALTX) made a tender offer to acquire 37.3% stake in Genkyotex SA (ENXTPA:GKTX) for €12.1 million.

Calliditas Therapeutics AB (publ) to Report Q1, 2021 Results on May 13, 2021

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço